Literature DB >> 10542040

Apatite cement containing antibiotics: efficacy in treating experimental osteomyelitis.

S Sasaki1, Y Ishii.   

Abstract

Osteomyelitis is generally treated by the systemic administration of antibiotics and continuous irrigation after curettage of the lesion, and bone graft is performed secondarily to treat any bone defect. This treatment is associated with major invasion, and also has adverse effects on other organs. If a superior bone filling material were to be developed that allowed high concentrations of antibiotics that acted only locally, and allowed bone formation at the same time, an ideal method of treating osteomyelitis would become available. We created an implant composed of calcium phosphate cement, gentamicin, and poly-L-lactic acid. The results of sustained-release testing in vivo and in vitro demonstrated the release of effective antibiotic concentrations over a 2-month period. Further, when an experimental model of osteomyelitis was produced in rabbits and the implant was inserted after bone marrow curettage, the implant proved effective in preventing the progression of osteomyelitis and in achieving local bone formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542040     DOI: 10.1007/s007760050117

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  3 in total

1.  [Animal models of osteomyelitis].

Authors:  T Kälicke; U Schlegel; C Kraft; C Wingenfeld; G Muhr; S Arens
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

2.  Testing of antibiotic releasing implant coatings to fight bacteria in combat-associated osteomyelitis - an in-vitro study.

Authors:  David Alexander Back; Nicole Bormann; Arash Calafi; Julie Zech; Leif Alexander Garbe; Martin Müller; Christian Willy; Gerhard Schmidmaier; Britt Wildemann
Journal:  Int Orthop       Date:  2016-02-23       Impact factor: 3.075

3.  Late infection of total knee arthroplasty inflamed by anti-TNFalpha, Infliximab therapy in rheumatoid arthritis.

Authors:  Takashi Yurube; Koichiro Takahi; Hajime Owaki; Takeshi Fuji; Masahiro Kurosaka; Minoru Doita
Journal:  Rheumatol Int       Date:  2009-05-16       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.